Nagakumar Bharatham
Principal Scientist-Cheminformatics at Transition Bio, Inc.- Claim this Profile
Click to upgrade to our gold package
for the full feature experience.
Topline Score
Bio
Mihir Daté
I had an opportunity to work with Kumar on verity of different projects at St Jude Children's Research Hospital. He is hard working, detailed oriented true professional. His diverse skill set in experimental as well as computational drug discovery research makes him unique team member who can integrate both aspects of research and manage technology effectively. He possess remarkable ability to oversight a project and analyze the bigger picture. I wish him well in his future endeavors. I think any employer will be fortunate to have him in their team.
Jake Slavish
I worked with Kumar for approximately two years on a bromodomain inhibitor project. Kumar provided insight from co-crystallographic data to guide future synthetic endeavors; his ideas provided routes towards selectivity within a highly homologous protein family. Kumar was a pleasure to work with, he understood the rigors of scientific research and was willing to set aside time to help others. I recommend Kumar for any promotions and positions he applies. Sincerely, Jake
Mihir Daté
I had an opportunity to work with Kumar on verity of different projects at St Jude Children's Research Hospital. He is hard working, detailed oriented true professional. His diverse skill set in experimental as well as computational drug discovery research makes him unique team member who can integrate both aspects of research and manage technology effectively. He possess remarkable ability to oversight a project and analyze the bigger picture. I wish him well in his future endeavors. I think any employer will be fortunate to have him in their team.
Jake Slavish
I worked with Kumar for approximately two years on a bromodomain inhibitor project. Kumar provided insight from co-crystallographic data to guide future synthetic endeavors; his ideas provided routes towards selectivity within a highly homologous protein family. Kumar was a pleasure to work with, he understood the rigors of scientific research and was willing to set aside time to help others. I recommend Kumar for any promotions and positions he applies. Sincerely, Jake
Mihir Daté
I had an opportunity to work with Kumar on verity of different projects at St Jude Children's Research Hospital. He is hard working, detailed oriented true professional. His diverse skill set in experimental as well as computational drug discovery research makes him unique team member who can integrate both aspects of research and manage technology effectively. He possess remarkable ability to oversight a project and analyze the bigger picture. I wish him well in his future endeavors. I think any employer will be fortunate to have him in their team.
Jake Slavish
I worked with Kumar for approximately two years on a bromodomain inhibitor project. Kumar provided insight from co-crystallographic data to guide future synthetic endeavors; his ideas provided routes towards selectivity within a highly homologous protein family. Kumar was a pleasure to work with, he understood the rigors of scientific research and was willing to set aside time to help others. I recommend Kumar for any promotions and positions he applies. Sincerely, Jake
Mihir Daté
I had an opportunity to work with Kumar on verity of different projects at St Jude Children's Research Hospital. He is hard working, detailed oriented true professional. His diverse skill set in experimental as well as computational drug discovery research makes him unique team member who can integrate both aspects of research and manage technology effectively. He possess remarkable ability to oversight a project and analyze the bigger picture. I wish him well in his future endeavors. I think any employer will be fortunate to have him in their team.
Jake Slavish
I worked with Kumar for approximately two years on a bromodomain inhibitor project. Kumar provided insight from co-crystallographic data to guide future synthetic endeavors; his ideas provided routes towards selectivity within a highly homologous protein family. Kumar was a pleasure to work with, he understood the rigors of scientific research and was willing to set aside time to help others. I recommend Kumar for any promotions and positions he applies. Sincerely, Jake
Experience
-
Transition Bio, Inc.
-
United States
-
Biotechnology Research
-
1 - 100 Employee
-
Principal Scientist-Cheminformatics
-
Oct 2022 - Present
Setting up computational medicinal chemistry facility to complement existing AI/ML resources. Setting up computational medicinal chemistry facility to complement existing AI/ML resources.
-
-
-
TDU
-
India
-
Higher Education
-
1 - 100 Employee
-
Research Supervisor
-
Feb 2020 - Present
-
-
-
University of Dundee
-
United Kingdom
-
Research Services
-
700 & Above Employee
-
Computational chemist @ Durg Discovery Unit (DDU)
-
Oct 2021 - Oct 2022
-
-
-
Bugworks Research Inc.
-
India
-
Biotechnology Research
-
1 - 100 Employee
-
Associate Director-Computational Drug Discovery
-
Nov 2019 - Oct 2021
-
-
Principal Scientist-Computational Drug Discovery
-
Nov 2017 - Nov 2019
-
-
Computational chemist
-
Nov 2014 - Oct 2017
-
-
-
Centre for Cellular and Molecular Platforms (C-CAMP)
-
India
-
Research Services
-
1 - 100 Employee
-
Technology Manager, Computational Drug Discovery
-
Nov 2014 - Oct 2017
-
-
-
St. Jude Children's Research Hospital - ALSAC
-
United States
-
Non-profit Organizations
-
700 & Above Employee
-
Postdoctoral Research Associate
-
Dec 2010 - Oct 2014
Structure based lead optimization for anti-cancer targets: MDM2 and MDM4 by • applying anchor based sampling strategy for docking nutlins [JCIM] • computationally aided re-purposing [WO2012/045018] • virtual screening for hit enrichment [to be submitted] Ligand interaction fingerprint/shape based virtual screening for lead identification against • BRDs • Plk1 • FGFR4 • SYK kinase targets by designing poly pharmacological inhibitors against related family members NMR structure refinement for highly flexible protein:ligand complexes for structure based drug design by MD simulations Application of constant pH MD simulations in targets where protonation states of amino acids play a crucial role in ligand binding pockets Show less
-
-
-
Nanyang Technological University Singapore
-
Singapore
-
Higher Education
-
700 & Above Employee
-
Research Fellow/Postdoc
-
Nov 2008 - Oct 2010
Proposed binding model of PI(3)P and UVRAG C2 domain was corroborated by experimental point mutations [Nature Cell Biology 2013] Contributed to target validation and inhibitor discovery for Plasmodium falciparum FKBP35 to develop novel compounds as antimalarial agents. [Current Medicinal Chemistry, 18 (12), pp. 1874-1889, Protein Science, 18 (10), pp. 2115-2124, Protein Science, 19 (8), pp. 1577-1586 ] Unraveled the Molecular Basis of Bcl-XL-p53 Interaction in comparison with conventional partners (Bad, Bak) through molecular modeling studies [PLoS One. 2011;6(10):e26014] Elucidated the role of VRK1 C-terminal extended loop with histone macro domain by molecular modeling studies (later confirmed by mutational experiments). [Journal of Biological Chemistry] Show less
-
-
-
GVK BIO
-
India
-
Research Services
-
700 & Above Employee
-
Senior Scientific Associate
-
Jan 2004 - Feb 2005
Project leader of a team of 10 members for Kinase Inhibitor Database developmentand in-charge for other target databases such as Proteases, GPCR’s, Ion-Channels,NHR’s and Phosphatases by enriching biological data from various literature sources(Journals, Patents, FDA/online sites and other various Internet sites etc.) using MDLsoftware’s like [ISIS Base, ISIS Draw]
-
-
Scientific Associate
-
Jan 2002 - Dec 2003
Inhibitor Database development for target databases such as Kinase,Proteases, GPCR's, Ion-Channels, NHR's and Phosphatases from variousliterature sources (Journals, Patents, FDA websites and other various Internetsites etc.) using MDL softwares like [ISIS Base, ISIS Draw]Drug Design and development of inhibitors for various targets through application of various computational techniques like performing Structure-based and Ligand-based drug design.
-
-
-
-
Project Trainee
-
Aug 2001 - Dec 2001
-
-
Education
-
2005 - 2008
Gyeongsang National University
Doctor of Philosophy (PhD), Computer aided drug design -
1999 - 2001
Nagarjuna University
Master of Science, Biochemistry -
1996 - 1999
Sri Venkateswara University
Bachelor of Science, Biochemistry
Community
